Enoxaparin is an injectable blood thinner that helps prevent and treat harmful blood clots. It belongs to a class of medicines called low molecular weight heparins (LMWHs), used to prevent and treat deep vein thrombosis, pulmonary embolism, and certain heart-related clotting conditions. It is a prescription-only medicine.

• Therapeutic Class: Anticoagulant (blood thinner).

• Pharmacological Class: Low molecular weight heparin (LMWH).

• Drug Family: Heparin derivatives.

• ATC Classification: B01AB05 (Enoxaparin).

Approved: Prevention of deep vein thrombosis (DVT) after certain surgeries or in medically ill patients with restricted mobility; treatment of DVT and pulmonary embolism; prevention of clotting complications in unstable angina and certain heart attacks.

Commonly used for: Hospitalised patients at risk of clotting, patients recovering from major surgery, and patients with confirmed blood clots needing treatment.

Off-label use (only under medical guidance): Sometimes used in pregnancy for clot prevention/treatment, as it doesn't cross the placenta significantly, though this is a specialist decision.

● Injection (prefilled syringe, subcutaneous): commonly available in 20 mg, 40 mg, 60 mg, 80 mg, 100 mg, 120 mg, and 150 mg strengths.

Enoxaparin works by boosting the activity of a natural protein in the blood called antithrombin, which then inactivates clotting factors (mainly Factor Xa, and to a lesser extent thrombin/Factor IIa). This reduces the blood's ability to form new clots, helping prevent or treat conditions like DVT and pulmonary embolism.

• Standard dose (DVT/PE prophylaxis): 40 mg subcutaneously once daily, or 30 mg twice daily depending on the surgical/medical context.

• Condition-wise dose (DVT/PE treatment): 1 mg/kg subcutaneously every 12 hours, or 1.5 mg/kg once daily as an alternative regimen.

• Route: Subcutaneous injection, typically into the abdomen; not given intramuscularly.

• Renal impairment: Dose reduction required in severe renal impairment (creatinine clearance under 30 mL/min).

• Missed dose: Take as soon as remembered unless close to the next dose; contact the prescribing doctor for guidance rather than doubling up.

• Overdose: Can cause serious bleeding; managed with close monitoring and, in severe cases, a reversal agent (protamine sulfate) under medical supervision.

• Common: Bruising or pain at the injection site, and mild bleeding (e.g., gums, nosebleeds).

• Serious: Major bleeding, heparin-induced thrombocytopenia, and spinal or epidural hematoma in patients receiving spinal/epidural anesthesia or spinal puncture (boxed warning).

• Emergency symptoms: Signs of major bleeding, sudden weakness or numbness (possible spinal hematoma if recently had spinal procedures), or signs of a severe allergic reaction.

• Recovery advice: Mild injection-site bruising is common and generally not a concern; any unusual or heavy bleeding should be reported to the treating doctor promptly.

• Pregnancy: Used when clearly needed, as it's often the anticoagulant of choice in pregnancy due to not crossing the placenta significantly.

• Breastfeeding: Generally considered compatible, discussed with the treating doctor.

• Liver disease: Used with caution; bleeding risk may be increased.

• Kidney disease: Requires dose adjustment in severe impairment; anti-Xa level monitoring may be used.

• Elderly: Used with care, particularly those with low body weight or reduced kidney function.

• Children: Used in some pediatric settings under specialist guidance; formal dosing less established than in adults.

● Other anticoagulants or antiplatelet drugs (warfarin, aspirin, clopidogrel, NSAIDs): increases the risk of bleeding when combined.

● Drugs affecting potassium (e.g., ACE inhibitors, potassium-sparing diuretics): enoxaparin can raise potassium levels; combined use requires monitoring.

● Thrombolytics (clot-dissolving drugs): significantly increases bleeding risk if used together.

● Herbal supplements with blood-thinning effects (e.g., ginkgo, garlic supplements in high doses): may add to bleeding risk.

● Platelet counts, especially between days 4 and 14 of treatment, to screen for heparin-induced thrombocytopenia.

● Kidney function tests, particularly before starting and during treatment in at-risk patients.

● Signs of bleeding at every visit.

● Anti-Xa levels in special populations when monitoring is indicated.

Dalteparin, Fondaparinux (other injectable anticoagulants); Rivaroxaban, Apixaban (oral anticoagulants).

Often used as a bridge before switching to an oral anticoagulant, or alongside aspirin/other antiplatelet drugs in specific heart-related clotting protocols under close medical supervision.

● Anticoagulant (Blood Thinner) Medicines

● DVT/PE Prevention and Treatment

● Low Molecular Weight Heparins

Understanding Deep Vein Thrombosis (DVT): Symptoms, Causes, and Risks

1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020164s129lbl.pdf

2. https://www.drugs.com/dosage/lovenox.html

The information on this page is for educational purposes only and is not a substitute for medical advice. Please consult your doctor to know if this treatment is appropriate for your condition.